Bio-Alcamid risks when used for facial lipoatrophy

Results from a safety study on the risks of using Bio-Alcamid to treat HIV-related facial fat loss (lipoatrophy) were presented at the 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in London earlier this month.

Researchers collected long term follow up data from over 260 HIV-positive people using Bio-Alcamid in Toronto and reported a conservative estimate of serious complications in at least 5% of cases.

Their results support accumulating safety concerns that should limit future use of Bio-Alcamid in HIV-positive people.

Read the full article.